South Korea · Delayed Price · Currency is KRW High Tech Pharm Statistics
Total Valuation
High Tech Pharm has a market cap or net worth of KRW 111.12 billion. The enterprise value is 108.14 billion.
| Market Cap | 111.12B |
| Enterprise Value | 108.14B |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
High Tech Pharm has 10.63 million shares outstanding.
| Current Share Class | 10.63M |
| Shares Outstanding | 10.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.72% |
| Owned by Institutions (%) | 0.26% |
| Float | 5.82M |
Valuation Ratios
The trailing PE ratio is 9.32.
| PE Ratio | 9.32 |
| Forward PE | n/a |
| PS Ratio | 1.60 |
| PB Ratio | 0.83 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 9.07 |
| EV / Sales | 1.56 |
| EV / EBITDA | 6.07 |
| EV / EBIT | 8.81 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.87, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.87 |
| Quick Ratio | 1.95 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | -0.01 |
| Interest Coverage | 2,135.25 |
Financial Efficiency
Return on equity (ROE) is 9.27% and return on invested capital (ROIC) is 8.03%.
| Return on Equity (ROE) | 9.27% |
| Return on Assets (ROA) | 5.28% |
| Return on Invested Capital (ROIC) | 8.03% |
| Return on Capital Employed (ROCE) | 9.12% |
| Weighted Average Cost of Capital (WACC) | 4.40% |
| Revenue Per Employee | 1.07B |
| Profits Per Employee | 183.50M |
| Employee Count | 65 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.23 |
Taxes
In the past 12 months, High Tech Pharm has paid 2.58 billion in taxes.
| Income Tax | 2.58B |
| Effective Tax Rate | 17.76% |
Stock Price Statistics
The stock price has decreased by -20.58% in the last 52 weeks. The beta is 0.03, so High Tech Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.03 |
| 52-Week Price Change | -20.58% |
| 50-Day Moving Average | 11,445.40 |
| 200-Day Moving Average | 14,058.45 |
| Relative Strength Index (RSI) | 37.51 |
| Average Volume (20 Days) | 31,285 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, High Tech Pharm had revenue of KRW 69.41 billion and earned 11.93 billion in profits.
| Revenue | 69.41B |
| Gross Profit | 18.98B |
| Operating Income | 12.27B |
| Pretax Income | 14.50B |
| Net Income | 11.93B |
| EBITDA | 17.81B |
| EBIT | 12.27B |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 3.00 billion in cash and 20.57 million in debt, with a net cash position of 2.98 billion or 280.16 per share.
| Cash & Cash Equivalents | 3.00B |
| Total Debt | 20.57M |
| Net Cash | 2.98B |
| Net Cash Per Share | 280.16 |
| Equity (Book Value) | 134.05B |
| Book Value Per Share | n/a |
| Working Capital | 64.77B |
Cash Flow
In the last 12 months, operating cash flow was -904.70 million and capital expenditures -1.41 billion, giving a free cash flow of -2.31 billion.
| Operating Cash Flow | -904.70M |
| Capital Expenditures | -1.41B |
| Depreciation & Amortization | 5.54B |
| Net Borrowing | -7.97B |
| Free Cash Flow | -2.31B |
| FCF Per Share | -217.59 |
Margins
Gross margin is 27.34%, with operating and profit margins of 17.68% and 17.18%.
| Gross Margin | 27.34% |
| Operating Margin | 17.68% |
| Pretax Margin | 20.90% |
| Profit Margin | 17.18% |
| EBITDA Margin | 25.66% |
| EBIT Margin | 17.68% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 1.44%.
| Dividend Per Share | 150.00 |
| Dividend Yield | 1.44% |
| Dividend Growth (YoY) | 50.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 13.37% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.44% |
| Earnings Yield | 10.73% |
| FCF Yield | -2.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
High Tech Pharm has an Altman Z-Score of 8.78 and a Piotroski F-Score of 4.
| Altman Z-Score | 8.78 |
| Piotroski F-Score | 4 |